glp-1 hub podcast Hub: Support, Community, and Weight Loss S6.E8: My Life on GLP1:

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) may have a welcome benefit in addition to weight loss and glycemic control, with new data presented at ObesityWeek, the annual meeting of the Obesity Society, showing that use of these medications is associated with a reduction in problematic alcohol use

Previously, Hilary reported for ABC News Radio, Fortune, Forbes, and Al Jazeera America

This study was limited in scope: Conducted on 24 rats, not humans Administered a single dose Designed only to demonstrate that some absorption is possible Importantly, the study itself includes this disclaimer: This proof-of-concept study is not intended to provide guidance on the sublingual dosing of semaglutide in humans, or dosing conversion from other forms to sublingual administration. This means the only research behind these products cannot confirm whether they work in humans or provide guidance on appropriate dosing

"You can have an upset stomach, some diarrhea, nausea, but most of those are limited," Davis said